post-earn call takeaway
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
highlights-mostli increment beyond press releas morn quick-tak
-still top large-cap pick expect put distanc competitor
cours year switch studi result solid super close stat sig endpoint
soliri lumpi latin america underli trend strong
might patient diagnos use soliri due frequent inject may
opportun continu expand pipelin licens drive long-term
consensu number higher reflect consensu
expect go switch studi low nave studi probabl
upsid surpris help enabl rapid adopt curv
highlight detail outlook
-a top long-term pick lower pt reflect rova-t setback hadnt adjust model
note stellar perform hcv franchis remind remain
expert market access- even first market
us humira impact destock without would y/i growth ou
benefit time shipment
humira small impact co-pay accumul patient drive co-pay cost
ou humira declin project eros curv front-end load
hcv guidanc increas new us share
rova-t still discuss file strategi eu
venclexta beyond r/r cll zero aml myeloma opportun
revis estim pt fall reflect rova-t file setback
updat chart earn call updat
commentari around product serial around quarter includ
line revenueglob oper sale fx oper growth doubl growth digitu growth rheum doubl digit derm gi cd/uc share ps hs major formulari chang leader across categoriesrobust market ra spa psoriasi crohn uc posit vari retail inventori destock larg specialti pharci exclud impact growth ex-u benefit shipment time exclud impact growth high singl digit tender time inventori half month half month half month half monthimbruvicaglob oper cll market share leader across line cll market cll market sharestrong del ger/frn/ashar loss price erosionmor performancecontribut contract cycl esp sharepar acccess across cover live usclos us market share access cover live mavyret sale total primarili daa failur patient neg partnership account partnership partnership partnership account exchang hedg leverag rule equiti comp pronounc benefit time compens compani reportsadjust tax rateadjust epscreonadj gross marginadjust salesadjust sg salesoper marginhumiraviekiramavyretduopaabbv histor quarter perform commentari april
serial guidanc updat
growth oper fx minim fx compound-annual-growth-rate fx oper fx oper fx fx oper humira annual mid-high teensmid/high teensmid/high teensmid/high teen teenshigh teenslow teen ou annual mid-singl digitmid-singl fx approach mid-mid-singlepeak qmid-singl volum fx mid singlemid-single-digit qhigh-singl prior w/w annual product annual androgen creon mid-high singl lupron synagi synthroid flatmavyret deliv multi-billion peakglob hcv equal split us ou market creon growth duodopa androgel zinbryta synagi lupron synthroid flatproject full year hcv sale hcv approach us sale gross margin weak usd may impact qlower synagi expect sale sale margin expens tax rate increas next year approach also approach ep y/i non-cash non-cash sourc compani reportsannu guidanc start year unless indic april
roll commentari around pipelin
fda decis fda approv soongvhd data cll w/ gazyva dlbcl w/ r-chop data interim shine mcl mcl later abbvpotenti interim nhl data readout dlbcl unfit cll/sll interim data cll studi young fit watch wait patient on-going data cll studi young fit watch wait patient on-going data snda submiss mcl dlbcl potenti snda submiss mcl dlbcl murano r/r cll murano r/r cll readout come monthssnda submiss r/r cll eu potenti approv venclexta r/r cllsnda submiss r/r cll complet expect approv r/r cll posit feedback cll studi on-going inc comb imbruvica older/comorbid data on-going studi initi studi mainten data aml mm submit snda aml potenti approv late snda aml receiv induct therapi data aml myeloma aml on-going data inhl dlbcl later pivot mm data mm target subset fairli substanti patient good fit ra studi ye next month beyond biolog failur cdmard ra pivot come month select beyond select-monotherapi launch ra pivot select-compar select- ra pivot trial remain nda submiss select-compar data eular june select-earli come month submit nda commerci expet cd ddw start start cd later a/ uc ad start uc start giant cell arter ad uc giant cell arter report full ad aad meet ad on-going start u/c soonprogress studi cd uc ad ad later on-going psoriat arthriti cd also evalu psoriasi studi later launch psoriasi studi later file launch bla psoriasi bla psoriasi expect fda approv bla ema applic submit cd soon start u/c cd start uc cd uc cd expect begin studi uc start start triniti normal yr surviv file triniti sclc triniti triniti sclc top-line data present data triniti data file acceler approv sclcmaru chemo rova-t opdivo yervoy sclc start taho sclc combo i/o data meru/taho data combo i/o data meru/taho data combo i/o data taho data expect basket studi data sclc sclc sclc otherposs addit data neuroendocrin basket studi gbm gbm potenti gbm data potenti gbm trial on-going file gbmongo gbm studyfil endometriosi endometriosi present asrm congress end octprior review grant pdufa expect endometriosispdufa fibroid us e/m could opioid pain build market fibroid uterin fibroid top-line data announc uterin fibroid data present medic confer regulatori submiss uterin fibroid approv approv expect greatest impact multi-billioncfroom improv benefit pt move toward mid phase program clinic sever addit move clinic yearmultipl program advanc multipl modal target data colorect cancer data ovarian colorect cancer ovarian cancer data advanc tnb nsclc fail data nsclcvela data nsclc compani upadacitinibrinsakizumababbv product outlook commentaryupadacitinib safeti profile- unblind pivot studi patient dvt/pe compar patient dvt/pe compar imbal lower dose includ program platelets- modest decreas increas baselin time april
deriv pt use dcf discount rate termin growth rate
discount rate standard rate appli across derisk biopharma compani reflect believ
appropri return sharehold termin growth rate reflect durabl natur
clearli humira domin product model still assum repres total model revenu
current framework biosimilar adopt chang humira method use patent fall
multipl biosimilar launch simultan creat pent-up precipit impact sale share could
suffer rova-t elagolix import pipelin program either stumbl share could see modest downsid
deriv valuat base dcf use discount rate appli
commerci stage biotech compani termin growth rate reflect optimist outlook
durabl compani franchis includ contribut soliri myasthenia gravi nmo given
concern scientif merit indic includ product revenu reflect
potenti busi develop
risk price target includ intensifi competit threat formid biopharma compani along
potenti amplifi price pressur failur build compel develop pipelin stumbl
develop trial would expect litani downgrad substanti re-rat
articl articl
time dissemin april et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu shenston huang primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
report approv and/or distribut evercor group llc evercor group licens broker-deal regul
industri regulatori author finra intern strategi invest group uk limit isi uk authoris regul
unit kingdom financi conduct author institut sale trade research busi evercor group isi
uk collect oper global market brand name evercor isi evercor isi evercor group isi uk subsidiari
evercor partner inc evercor partner trademark logo servic mark shown report regist trademark
analyst associ respons prepar report receiv compens base variou factor includ evercor partner
total revenu portion gener affili invest bank transact evercor isi seek updat research
appropri variou regul may prevent happen certain instanc asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgment
evercor isi gener prohibit analyst associ member household maintain financi interest secur
compani analyst area coverag except polici requir specif approv member complianc
depart ownership subject complianc applic regul disclosur evercor isi also prohibit analyst associ
member household serv offic director advisori board member employe compani analyst
report may includ tactic call describ near-term event catalyst affect subject compani market overal
expect short-term price impact equiti share subject compani tactic call separ analyst
long-term recommend outperform under-perform reflect stock forward expect return formal rate
may differ target price recommend reflect analyst long-term view
applic current disclosur regard subject compani cover report avail offic evercor isi
obtain write evercor group llc attn complianc fifth avenu floor new york ny
evercor partner affili respect director offic member employe may interest
qualifi hold issuer mention report evercor partner affili may busi relationship
compani mention report
addit inform secur financi instrument mention report avail upon request
evercor isi recommend base stock total forecast return next month total forecast return equal
expect percentag price return plu gross dividend yield divid stock coverag three primari rate categori
outperform total forecast return expect greater expect total return analyst coverag univers
total forecast return expect line expect total return analyst univers
under-perform total forecast return expect less expect total return analyst univers
coverag suspend rate target price remov pursuant evercor isi polici evercor act advisori
capac merger strateg transact involv compani certain circumst
rate suspend evercor isi suspend rate target price stock suffici fundament basi
determin legal regulatori polici constraint around publish rate target price previou rate target price
longer effect compani reli upon
prior octob coverag suspend rate suspend categori includ categori suspend
finra requir member use rate system term buy hold/neutr sell equat
rate categori purpos evercor isi rate distribut outperform
under-perform rate equat buy hold sell respect
prior march evercor isi recommend base stock total forecast return next month
buy total forecast return expect greater
hold total forecast return expect greater equal less equal
sell total forecast return expect less
octob evercor partner acquir intern strategi invest group llc isi group isi uk acquisit
transfer evercor group research sale trade busi isi group decemb combin research sale
trade busi transfer back evercor group intern reorgan sinc acquisit combin research sale
trade busi oper global market brand name evercor isi
isi group isi uk
prior octob rate system isi group llc isi uk base risk adjust total return
buy return
neutral return
cautiou return
disclosur purpos isi group isi uk rate view follow strong buy buy equat buy neutral equat hold
